Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
Weeks after earning CEO's stamp of approval, a Novartis skin drug loses head-to-head battle with standard of care
With a jam-packed pipeline to parse, Novartis chief Vas Narasimhan has helped investors out in the past by highlighting a few key programs his …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
